{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088168","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.764179+00:00","generated_at":"2026-05-19T01:40:58.616069+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification","bullets":["Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.","Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.","Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088168","json":"https://secwatch.observer/filing/0000950170-25-088168.json","markdown":"https://secwatch.observer/filing/0000950170-25-088168.md","text":"https://secwatch.observer/filing/0000950170-25-088168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/0000950170-25-088168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/glto-20250618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:40:58.616069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}